GlassScriptPhysician profile
Nathaniel V Alvis
NPI 1861634008
$6,494.53
in general payments reported to CMS, 2019-2025
40 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $801 · 2021: $1,016 · 2022: $1,050 · 2023: $992 · 2024: $906 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $882.93 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $658.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $535.01 | 2019-2024 | Farxiga, Fasenra |
| Pfizer INC. | $418.26 | 2019-2025 | |
| Amgen INC. | $387.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Mylan Specialty L.P. | $348.97 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.95 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $311.09 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.00 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $258.51 | 2023-2025 | Gemtesa |
| Abbvie INC. | $248.48 | 2021-2025 | Ubrelvy, Vraylar |
| Otsuka America Pharmaceutical, INC. | $164.87 | 2022-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $123.09 | 2021-2022 | |
| Lundbeck LLC | $123.09 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.54 | 2020-2024 | Jardiance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Alvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.